Literature DB >> 29275524

Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases.

Guillaume Peyraga1,2, Delphine Caron3,4, Thibaut Lizee3,4, Yann Metayer5, Anne-Lise Septans6, Yoann Pointreau3, Fabrice Denis3, Gerard Ganem3, Cedrik Lafond3, Sophie Roche3, Olivier Dupuis3.   

Abstract

OBJECTIVE: The palliative treatment for cervico-thoracic spinal metastases is based on a three-dimensional conformal radiation therapy (3D-CRT). Digestive toxicities are common and cause a clinical impact frequently underestimated in patients. We performed a retrospective study of digestive side effects occurring after palliative 3D-CRT for cervico-thoracic spinal metastases. PATIENTS AND METHODS: All patients receiving palliative 3D-CRT at Jean Bernard Center from January 2013 to December 2014 for spinal metastases between the 5th cervical vertebra (C5) and the 12th thoracic vertebra (T12) were eligible. Three-dimensional conformal RT was delivered by a linear accelerator (CLINAC, Varian). Premedication to prevent digestive toxicities was not used. Adverse events ("esophagitis" and "nausea and/or vomiting") were evaluated according to the NCI-CTCae (version 4).
RESULTS: From January 2013 to December 2014, 128 patients met the study criteria. The median age was 68.6 years [31.8; 88.6]. Most patients (84.4%) received 30 Gy in 10 fractions. The median overall time of treatment was 13 days [3-33]. Forty patients (31.3%) suffered from grade ≥ 2 of "esophagitis" (35 grade 2 (27.4%) and 5 grade 3 (3.9%)). Eight patients (6.3%) suffered from grade ≥ 2 of "nausea and/or vomiting" (6 grade 2 (4.7%), 1 grade 3 (0.8%), and 1 grade 4 (0.8%)).
CONCLUSION: The high incidence of moderate to severe digestive toxicities after palliative 3D-CRT for cervico-thoracic spinal metastases led to consider static or dynamic intensity-modulated radiation therapy (IMRT) to reduce the dose to organ at risk (the esophagus and stomach). Dosimetric studies and implementation in the clinic should be the next steps.

Entities:  

Keywords:  Digestive toxicities; Esophageal toxicities; Intensity-modulated radiation therapy; Radio-induced esophagitis; Spinal metastases

Mesh:

Year:  2017        PMID: 29275524     DOI: 10.1007/s00520-017-4001-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  32 in total

1.  Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer.

Authors:  H Choy; K LaPorte; E Knill-Selby; P Mohr; Y Shyr
Journal:  Semin Radiat Oncol       Date:  1999-04       Impact factor: 5.934

2.  A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012.

Authors:  Shannon E Fogh; Snehal Deshmukh; Lawrence B Berk; Amylou C Dueck; Kevin Roof; Sherif Yacoub; Thomas Gergel; Kevin Stephans; Andreas Rimner; Albert DeNittis; John Pablo; Justin Rineer; Terence M Williams; Deborah Bruner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-23       Impact factor: 7.038

3.  "Anatomically-correct" dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics.

Authors:  Daniel Kahn; Sumin Zhou; Sung-Ja Ahn; Donna Hollis; Xiaoli Yu; Thomas A D'Amico; Timothy D Shafman; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

4.  Clinical and dosimetric predictors of radiation-induced esophageal toxicity.

Authors:  P D Maguire; G S Sibley; S M Zhou; T A Jamieson; K L Light; P A Antoine; J E Herndon; M S Anscher; L B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-08-01       Impact factor: 7.038

Review 5.  Stereotactic Body Radiotherapy in the Treatment of Spinal Metastases.

Authors:  Evangelia Katsoulakis; Kiran Kumar; Ilya Laufer; Yoshiya Yamada
Journal:  Semin Radiat Oncol       Date:  2017-03-16       Impact factor: 5.934

6.  Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.

Authors:  Ashish B Patel; Martin J Edelman; Young Kwok; Mark J Krasna; Mohan Suntharalingam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-15       Impact factor: 7.038

7.  Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma.

Authors:  Jeffrey Bradley; Joseph O Deasy; Soeren Bentzen; Issam El-Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

8.  Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy.

Authors:  Robin Wijsman; Frank Dankers; Esther G C Troost; Aswin L Hoffmann; Erik H F M van der Heijden; Lioe-Fee de Geus-Oei; Johan Bussink
Journal:  Radiother Oncol       Date:  2015-09-02       Impact factor: 6.280

9.  Dosimetric and clinical predictors of radiation-induced lung toxicity in esophageal carcinoma.

Authors:  Shu-Chai Zhu; Wen-Bin Shen; Zhi-Kun Liu; Juan Li; Jing-Wei Su; Yu-Xiang Wang
Journal:  Tumori       Date:  2011 Sep-Oct

Review 10.  MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.

Authors:  Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad
Journal:  Cancer       Date:  2014-02-25       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.